The astrophysicist is using preimplantation genetic testing (PGT) to eliminate her future children’s risk of inheriting the ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo ...

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Endometrial Cancer.

“The benefits of RRM and RRSO have been shown for BRCA-mutation carriers without a prior history of cancer, but their impact for BRCA-mutation carriers with a history of early-onset breast ...

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase II drugs for Malignant Mesothelioma have a 42% phase ...

"The benefits of RRM and RRSO have been shown for BRCA-mutation carriers without a prior history of cancer, but their impact for BRCA-mutation carriers with a history of early-onset breast cancer ...

Millions of women around the world who had never heard of the BRCA gene became aware that this mutation links to devastatingly early deaths in generation upon generation of affected families ...

"This global study provides the first evidence that risk-reducing surgeries improve survival outcomes among young BRCA-mutation carriers with a prior history of early-onset breast cancer," said ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Plggy Bank for Women Competing with Yangtze River Pharmaceuticals and Shijiazhuang No. 4 Pharmaceuticals! Shijiazhuang Pharmaceuticals disrupts the ...